Articles

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2012

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.564 views

Read more →

Regulatory

Published on 25 March 2020

Regulatory pathway for approval of ‘biosimilars’ in Iran

Abstract: Iran was the first country in the MENA (Middle East and North Africa) region to publish a legal framework for the registration of biosimilars. This framework is defined by...

Author(s): Jalal Naeli, MD

biopharmaceuticals, Iran, reference medicinal product

2.554 views

Read more →

Published on 27 September 2017

2017/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2017, Issue 3 Commentary Patent expiry and costs for anti­cancer medicines for clinical use Original Research A survey of Australian prescribers’ views...

2.553 views

Read more →

Published on 28 January 2019

2018/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s seventh volume Editorial Nomenclature for biosimilars; a continuing thorny issue Original Research Ongoing activities to influence the prescribing of proton...

2.534 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2013

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.533 views

Read more →

Abstracted Scientific Content

Published on 21 May 2021

Repurposing non-oncology drugs for cancer treatment

Submitted: 15 March 2021; Revised: 17 March 2021; Accepted: 18 March 2021; Published online first: 24 March 2021 Cancer is one of the leading causes of mortality in the world...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2021.1002.011

2.517 views

Read more →

Published on 31 October 2016

2016/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2016, Issue 3 Letters to the Editor Is the EU ready for non-biological complex drug products? Commentary Biosimilars: achieving long-term savings and...

2.508 views

Read more →

Published on 27 November 2019

2019/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2019, Issue 3 Commentary Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective Original Research Pharmacy chain drives...

2.483 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2014

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.479 views

Read more →

Published on 21 June 2017

2017/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2017, Issue 2 Editorial Trends and challenges in biosimilars pricing and reimbursement policies in Europe and beyond Commentary Strategies...

2.474 views

Read more →

Editor's Letter

Published on 24 March 2020

Editor’s introduction to the initial issue of the ninth volume of GaBI Journal

The current coronavirus pandemic raises some important questions relevant to generic and/or biosimilar products. While still unproven, there are some indications that approved antiviral compounds exist which might be able...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2020.0901.001

2.449 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2015

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI...

2.418 views

Read more →